Objectives: Heart transplant is the treatment of choice for patients with end-stage heart failure who remain symptomatic despite optimal medical therapy. The primary indications for heart transplant worldwide have been nonischemic cardiomyopathy and ischemic cardiomyopathy. For the 2 indications, patients differ in underlying pathomechanisms leading to their disease and consecutively in relevant comorbidities. However, the influence of an indication of ischemic or nonischemic cardiomyopathy for heart transplant on recipient outcomes posttransplant remains contro-versial. Here, we investigated whether ischemic or nonischemic cardiomyopathy indication were associated with patient morbidity and mortality after heart transplant.
Materials and Methods: We included all patients undergoing heart transplant in our center between September 2010 and June 2021 (n = 218). Recipients were divided into 2 groups related to their indication: ischemic (n = 92; 42%) and nonischemic cardiom-yopathy (n = 126; 58%). Recipient and donor variables were reviewed and compared, including peri- and postoperative characteristics and recipient survival up to 5 years posttransplant.
Results: Although patients with nonischemic cardio-myopathy were significantly younger (51.7 vs 59.1 years; P < .001), had fewer previous cardiac surgeries (56% vs 75%; P = .01), and less frequent severe infections or sepsis (19% vs 32%; P = .03), other outcome-related parameters such as need for extracorporeal life support posttransplant (26% vs 33%), rejection within index stay (7% vs 8%), and survival after 30 days (88% vs 92%), 90 days (85% vs 88%) or 1 year (76% vs 77%) were different.
Conclusions: In this retrospective analysis, although barring different baseline characteristics, ischemic versus nonischemic recipient diagnosis was not associated with outcome or survival after heart transplant.
Key words : Cardiac transplantation, Ischemic cardiomyopathy, Nonischemic cardiomyopathy, Recipient diagnosis, Short-term survival
Heart transplant is the treatment of choice for patients with end-stage heart failure who remain symptomatic despite optimal medical therapy. The primary indications for heart transplant worldwide are nonischemic cardiomyopathy (non-ICM) and ischemic cardiomyopathy (ICM).1 For the 2 indications, patients differ in underlying pathomechanisms leading to their disease and consecutively in relevant comorbidities. Ischemic cardiomyopathy has been used to describe significantly impaired left ventricular function that results from coronary artery disease. Ischemic cardiomyopathy can result from irreversible loss of myocardium as a result of prior myocardial infarc-tion or from reversible loss of contractility due to chronically ischemic but still viable myocardium.2-5 To distinguish those from other causes of heart failure with severely reduced ejection fraction, non-ICM is defined as all diseases affecting heart muscle associated with cardiac dysfunction, taking into consideration etiology as well as the dominant pathophysiology.3,6 This definition includes dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia, and other unclassified cardiomyopathies (eg, noncompaction cardiomyopathy).
Coronary artery disease is often associated with other cardiovascular diseases, whereas most non-ICMs show isolated cardiac phenotypes.7-9 Therefore, it could be argued that ICM versus non-ICM as recipient indication for heart transplant could potentially influence outcomes after heart transplant. However, whether these 2 indications for heart transplant influence recipient outcomes post-transplant remains controversial.1,10 Here, we investigated whether an indication of ICM versus non-ICM for heart transplant was associated with recipient morbidity and mortality after heart transplant.
Materials and Methods
The study conformed to the principles of the Declaration of Helsinki and Good Clinical Practices. All subjects participated voluntarily and gave informed consent. The study was approved by our local ethics committee.
Patients and study design
Between September 2010 and June 2021, 218 patients underwent heart transplant in our center. Recipients were divided into 2 groups related to their indication: ICM (n = 92; 42%) and non-ICM (n = 126; 58%).
All relevant recipient and donor variables were reviewed and compared between the 2 recipient indication groups. Recipient and donor charac-teristics and recipient survival data after up to 5 years, including 30 and 90 days and 1 year posttransplant, where applicable, were collected.
Statistical analyses and preparation of figures
Qualitative (dichotomous) variables were compared by the Pearson chi-square test or, when its application conditions were not met, by the Fisher exact test. Quantitative variables were compared by the t test. The tests were performed bilaterally, and the threshold of significance was set at P = .05. Statistical analysis was performed using GraphPad Prism and IBM SPSS Statistics software (SPSS). Figures were created using GraphPad Prism, Microsoft PowerPoint, and IBM SPSS.
Among the 218 included recipients (92 with ICM; 126 with non-ICM), patients with non-ICM were significantly younger (51.7 vs 59.1 years; P < .001), had fewer previous cardiac surgeries (56% vs 75%; P = .01), and lower incidence of ventricular assist device support pretransplant (46% vs 61%; P = .04). All other baseline characteristics were comparable, including sex, parameters of size mismatch, and comorbidities. Furthermore, no statistically relevant differences could be observed in laboratory values, including recipient sodium and potassium levels as well as creatinine, bilirubin, lactate dehydrogenase, and hemoglobin levels (Table 1).
Donors were comparable regarding all baseline characteristics, including age, sex, body mass index, left ventricular ejection fraction, and comorbidities. Furthermore, no statistically relevant differences in laboratory values could be observed, including donor potassium and sodium levels as well as hemoglobin and lactate dehydrogenase levels (Table 2).
Perioperative morbidity and mortality
Regarding peri- and postoperative parameters, both groups did not differ in total or cold graft ischemia time, duration of surgery, time on mechanical ventilation, length of posttransplant hospital or intensive care unit stay or need for transfusion of packed red blood cells, platelets, or fresh frozen plasma (Table 3). Most patients received the bicaval technique for heart transplant. Cardioprotection was performed in all patients through cold storage with crystalloid cardioplegia. Regarding common postoperative morbidities, patients did not differ in the likelihood of kidney failure with hemodialysis posttransplant, neurological complications, incidence of acute graft rejection (>1R), or the need for mechanical life support posttransplant. However, recipients with non-ICM had less frequent incidences of severe infections or sepsis (19% vs 32%; P = .03).
Concerning early mortality, survival rates after 30 days (88% vs 92%), 90 days (85% vs 88%), and 1 year (76% vs 77%) were comparable between ICM and non-ICM recipients (Table 3). These results were confirmed by Kaplan-Meier survival analysis (Figure 1).
Only limited knowledge exists on the association of perioperative morbidity and mortality and recipient indication for heart transplant. Our goal was to investigate any differences between ischemic and nonischemic heart failure as the reason for heart transplant on outcomes posttransplant in a retros-pective analysis of 218 heart transplant recipients seen at our center over a 10-year period.
Our main finding was that, despite differing baseline characteristics and postoperative parameters, the ICM versus non-ICM recipient diagnosis did not influence short-term survival up to 1 year after heart transplant.
In our study cohort, 42% of recipients had ICMs and 58% had non-ICMs. This ratio was found to be comparable to data in the literature, where, between 1982 and 2018, around 40% of all recipients were diagnosed with ICM.1,11 In our study, patients with non-ICMs were significantly younger (52 vs 59 years), which can be explained by the underlying mechanism of heart failure in those patients with higher percentage of hereditary (genetic) causes. This also was similar to published data in a large cohort of heart transplant recipients that showed that only 32% of patients in the age group of 40 to 59 years were ICM patients, whereas in age group >70 years the percent of patients was 53%.1 On the other hand, donors of those recipients did not show perio-perative differences in both groups, including age, making donor age unlikely to be a significant confounder in our study.
Concerning preoperative parameters, ICM pati-ents versus non-ICM patients had a higher rate of previous cardiac surgeries (75% vs 56%), which can be explained by longer history of coronary artery disease (ie, previous need for coronary artery bypass graft). These results were similar to reported data where around 61% of all heart transplant patients had previous cardiac surgery.12 Furthermore, patients with non-ICM showed a lower incidence of ventricular assist device support pretransplant (46% vs 61%) than patients with ICM, as shown in a study with a larger cohort13 (44% vs 56%).
With respect to perioperative morbidity, although both groups did not differ in most parameters, recipients with non-ICM had fewer incidences of severe infections or sepsis (19% vs 32%) than recipients with ICM. This can be partly but not fully explained by the older-aged ICM cohort, as severity and mortality of sepsis are associated with higher age.14,15
Regarding early-term and midterm survival, we observed no differences between recipients with ICM and non-ICM before heart transplant. As previously shown, 30-day survival was also comparable to that shown in larger cohorts of heart transplant recipients (89% to 93%).16,17 However, compared with heart transplant recipients in the United States, the overall survival in the whole cohort was less, independently from our subgroup analysis on recipient diagnosis.1 This can be mainly explained by 2 factors. First, according to the International Society for Heart and Lung Transplantation database from 2010 to 2018, donor ages in Europe versus North America were extremely different, with median age difference of 17 years.1 Because higher donor age is associated with a higher mortality in heart transplant recipients,18 this leads to a need for acceptance of possibly worse organs in European countries, including Germany, compared with the United States. Second, in Europe, organ allocation through the waiting list is performed by categorization into 2 categories: regular or high-urgent. In the high-urgency-based system, progression of cardiac diseases leads to preferred organ allocation, and those with worse expected outcomes without transplant are therefore prioritized. To overcome these shortcomings, it is expected that a “Cardiac Allocation Score”19 will be introduced soon. However, presently, despite limited data from prospective studies, this shortcoming could potentially lead to a higher mortality in European versus US recipients. Both factors contributed to a lowered survival after 1 year between both systems, which then “drags along” the lowered survival after 5 years in our Kaplan-Meier survival analysis.
The influence of recipient indication for heart transplant on survival posttransplant remains controversial; however, published (retrospective) data have suggested mainly a small survival benefit in non-ICM versus ICM recipients.1,10,11 However, those cohorts included retrospective patient data from dif-ferent heart transplant eras, leading to a potential bias.
A major and obvious limitation of our study was its single-center and retrospective design, which included several generations of surgeons contributing to the data. Therefore, future studies with larger cohorts, preferably from the newest era of heart transplant, and studies having a prospective design are needed to confirm or decline the association of recipient diagnosis on survival.
In this retrospective analysis, although barring different baseline characteristics and perioperative morbidities, recipient indication of ICM versus non-ICM was not associated with survival after heart transplant.
Volume : 20
Issue : 6
Pages : 580 - 584
DOI : 10.6002/ect.2022.0091
From the 1Department of Cardiology, Pulmonology, and Vascular Medicine, the 2Cardiovascular Research Institute Düsseldorf, and the 3Department of Cardiac Surgery, Medical Faculty, Heinrich-Heine University, Duesseldorf, Germany
Acknowledgements: The authors thank the medical staff of the Department of Cardiac Surgery and the Department of Cardiology of the Medical Faculty and University Hospital of the Heinrich-Heine-University Düsseldorf for their continuous effort and contribution in the treatment of critically ill patients. The authors have not received any funding or grants in support of the presented research or for the preparation of this work and have no declarations of potential conflicts of interest.
Corresponding author: Udo Boeken, Department of Cardiac Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany
Phone: +49 211 81 18331
Table 1. Preoperative Recipient Parameters
Table 2. Preoperative Donor Parameters
Table 3. Peri- and Postoperative Parameters and Survival, Grouped by Heart Transplant Recipient Diagnosis Pretransplant (Ischemic Versus Nonischemic Cardiomyopathy).
Figure 1. Five-Year Kaplan-Meier Survival After Heart Transplant, Shown by Recipient Diagnosis